NCT06943755View on ClinicalTrials.gov

Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

440

Participants

Timeline

Start Date

July 21, 2025

Primary Completion Date

June 30, 2029

Study Completion Date

June 30, 2029

Conditions
Pancreatic Neuroendocrine Tumor (pNET)Extra-Pancreatic Neuroendocrine Tumor (epNET)
Interventions
DRUG

Zanzalintinib

Administered as specified in the treatment arm.

DRUG

Everolimus

Administered as specified in the treatment arm.

Trial Locations (9)

10029

RECRUITING

Exelixis Clinical Site #7, New York

22903

RECRUITING

Exelixis Clinical Site #3, Charlottesville

27710

RECRUITING

Exelixis Clinical Site #6, Durham

40536

RECRUITING

Exelixis Clinical Site #9, Lexington

49546

RECRUITING

Exelixis Clinical Site #1, Grand Rapids

63110

RECRUITING

Exelixis Clinical Site #5, St Louis

02215

RECRUITING

Exelixis Clinical Site #8, Boston

00909

RECRUITING

Exelixis Clinical Site #2, San Juan

00927

RECRUITING

Exelixis Clinical Site # 4, San Juan

Sponsors

Lead Sponsor

Exelixis
All Listed Sponsors
lead

Exelixis

INDUSTRY

NCT06943755 - Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors | Biotech Hunter | Biotech Hunter